Kintai Therapeutics Revenue and Competitors

Founded in 2016 by Flagship Labs, the innovation foundry of Flagship Pioneering, Kintai Therapeutics is uniquely focused on unlocking the power of the enteric signaling network and its signals throughout the body to fight disease and restore the health of patients. The company's Precision Enteric Medicineâ„¢ (PEMâ„¢) discovery and therapeutic platform is based on a deep understanding of the interconnected biology of the microbiome, gut immune system and enteric nervous system. Kintai has pioneered a new frontier in gut science, resulting in a unique understanding of a wealth of new genes, metabolites, and signaling molecules, leveraging these insights to rapidly translate into a highly actionable pipeline. The company's expertise in chemistry, human biology, experimental medicine, and artificial intelligence represents a biology discovery and therapeutic development engine to rapidly identify and deliver new medicines. Kintai's multidisciplinary approach has delivered a pipeline of 10+ programs across multiple therapeutic areas, including oncology, neurology, and immunology. Based in Cambridge, MA, Kintai believes that its core strengths lie in the hearts and minds of its talented employees who keep patients at the center of everything we do.